Your browser doesn't support javascript.
loading
A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer.
Jiang, Runze; Lu, Yi-Tsung; Ho, Hao; Li, Bo; Chen, Jie-Fu; Lin, Millicent; Li, Fuqiang; Wu, Kui; Wu, Hanjie; Lichterman, Jake; Wan, Haolei; Lu, Chia-Lun; OuYang, William; Ni, Ming; Wang, Linlin; Li, Guibo; Lee, Tom; Zhang, Xiuqing; Yang, Jonathan; Rettig, Matthew; Chung, Leland W K; Yang, Huanming; Li, Ker-Chau; Hou, Yong; Tseng, Hsian-Rong; Hou, Shuang; Xu, Xun; Wang, Jun; Posadas, Edwin M.
Afiliación
  • Jiang R; Beijing Genome Institute-Shenzhen, Shenzhen 51803, China.
  • Lu YT; Urologic Oncology Research Program, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
  • Ho H; Department of Statistics, University of California, Los Angeles, CA 90095, USA.
  • Li B; Institute of Statistical Sciences, Academia Sinica, Taipei 11529, Taiwan.
  • Chen JF; Beijing Genome Institute-Shenzhen, Shenzhen 51803, China.
  • Lin M; Urologic Oncology Research Program, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
  • Li F; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095, USA.
  • Wu K; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095, USA.
  • Wu H; Beijing Genome Institute-Shenzhen, Shenzhen 51803, China.
  • Lichterman J; Beijing Genome Institute-Shenzhen, Shenzhen 51803, China.
  • Wan H; Beijing Genome Institute-Shenzhen, Shenzhen 51803, China.
  • Lu CL; Urologic Oncology Research Program, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
  • OuYang W; Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA 90095, USA.
  • Ni M; Urologic Oncology Research Program, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
  • Wang L; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095, USA.
  • Li G; Beijing Genome Institute-Shenzhen, Shenzhen 51803, China.
  • Lee T; Beijing Genome Institute-Shenzhen, Shenzhen 51803, China.
  • Zhang X; Beijing Genome Institute-Shenzhen, Shenzhen 51803, China.
  • Yang J; California NanoSystems Institute, University of California, Los Angeles, CA 90095, USA.
  • Rettig M; The Guangdong Enterprise Key Laboratory of Human Disease Genomics, BGI-Shenzhen, Shenzhen 51803, China.
  • Chung LW; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095, USA.
  • Yang H; Departments of Medicine and Urology, University of California, Los Angeles, CA 90095, USA.
  • Li KC; Department of Medicine, Division of Hematology-Oncology, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA.
  • Hou Y; Urologic Oncology Research Program, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
  • Tseng HR; Beijing Genome Institute-Shenzhen, Shenzhen 51803, China.
  • Hou S; Princess Al Jawhara Centre of Excellence in Research of Hereditary Disorders, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  • Xu X; James D. Watson Institute of Genome Sciences, Zhejiang University, Hangzhou 310058, China.
  • Wang J; Department of Statistics, University of California, Los Angeles, CA 90095, USA.
  • Posadas EM; Institute of Statistical Sciences, Academia Sinica, Taipei 11529, Taiwan.
Oncotarget ; 6(42): 44781-93, 2015 Dec 29.
Article en En | MEDLINE | ID: mdl-26575023
ABSTRACT
Previous studies have demonstrated focal but limited molecular similarities between circulating tumor cells (CTCs) and biopsies using isolated genetic assays. We hypothesized that molecular similarity between CTCs and tissue exists at the single cell level when characterized by whole genome sequencing (WGS). By combining the NanoVelcro CTC Chip with laser capture microdissection (LCM), we developed a platform for single-CTC WGS. We performed this procedure on CTCs and tissue samples from a patient with advanced prostate cancer who had serial biopsies over the course of his clinical history. We achieved 30X depth and ≥ 95% coverage. Twenty-nine percent of the somatic single nucleotide variations (SSNVs) identified were founder mutations that were also identified in CTCs. In addition, 86% of the clonal mutations identified in CTCs could be traced back to either the primary or metastatic tumors. In this patient, we identified structural variations (SVs) including an intrachromosomal rearrangement in chr3 and an interchromosomal rearrangement between chr13 and chr15. These rearrangements were shared between tumor tissues and CTCs. At the same time, highly heterogeneous short structural variants were discovered in PTEN, RB1, and BRCA2 in all tumor and CTC samples. Using high-quality WGS on single-CTCs, we identified the shared genomic alterations between CTCs and tumor tissues. This approach yielded insight into the heterogeneity of the mutational landscape of SSNVs and SVs. It may be possible to use this approach to study heterogeneity and characterize the biological evolution of a cancer during the course of its natural history.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Biomarcadores de Tumor / Perfilación de la Expresión Génica / Genómica / Células Neoplásicas Circulantes Tipo de estudio: Prognostic_studies Límite: Humans / Male Idioma: En Revista: Oncotarget Año: 2015 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Biomarcadores de Tumor / Perfilación de la Expresión Génica / Genómica / Células Neoplásicas Circulantes Tipo de estudio: Prognostic_studies Límite: Humans / Male Idioma: En Revista: Oncotarget Año: 2015 Tipo del documento: Article País de afiliación: China